The Effect of Drug Deliveries and MDMA
A recent report by the Independent discussed how buying drugs has become as easy as buying ice cream. The report comes after experts named London as a city where cocaine is now delivered faster than pizza. According to the NHS, in the UK 2.7 million people between the ages of 16 and 59 took an illicit drug in 2015 and 2016 (roughly one in 12 adults). As a result, the Global Drug Survey are now looking at the impact of encrypted mobile phone messaging services and other methods that have enabled quick drug deliveries.
However, the drug problem is worldwide. In the US, life expectancy has fallen for the second consecutive year amid concerns of increased drug related deaths, the first multi-year drop since 1962 and 1963 according to the US National Centre for Health Statistics (NCHS). The NCHS documented that more than 63,600 US deaths in 2016 were due to drug related overdoses, a number that continues to increase.
MDMA has continued to appear in the news, after the deadly substance was responsible for the recent deaths of multiple teenagers in the UK. Also known as Ecstasy, MDMA is often described as the original designer drug due to its link with the dance culture in the late 80s and early 90s. Randox Toxicology’s DoA II panel tests for common drugs of abuse, including MDMA and generic opioids.
With the use of Biochip Array Technology, we have made multiplex testing capabilities possible. Our level of expertise in toxicology research and development allows us to adapt quickly to the ever-changing drug market influences and develop assays for current and novel drug trends.
|Analyte||Compound||Cross Reactivity %|
Purity is a concern with MDMA, which is regularly sold containing other fatal drugs. Newshub released information from Wendy Allison at KnowYourStuffNZ, who stated that only 20 percent of the drugs they tested in New Zealand contained MDMA. KnowYourStuffNZ’s website advises people to avoid certain pressed pills containing large amounts of MDMA. Theses pills include “Green Guccis”, a rectangular green pill with the Gucci logo and “Yellow Rolexes”, a yellow pill shaped like the Rolex crown logo. The comedown of Ecstasy can cause users to feel depression, whilst long term users can suffer from memory problems and anxiety. The use of the Class A drug has also been linked to liver, kidney and heart problems.
Our Randox Biosciences division is a trusted partner in supplying quality diagnostic solutions to the Clinical, Life Science, Pharmaceutical, Research and BioPharma industries.
Our molecular product range offers diagnostic, prognostic and predictive solutions across a variety of disease areas including sexually transmitted infections (STI), respiratory tract infection, colorectal cancer, familial hypercholesterolemia (FH) and cardiovascular disease (CVD).
Additionally, we can provide a wide range of assay formats including single nucleotide polymorphisms (SNP) genotyping, pathogen detection and mutation detection. The arrays are optimised for use with the Randox Evidence Investigator semi-automated, medium throughput bench-top biochip analyser.
One test, 10 results.
Our STI multiplex array II simultaneously detects 10 bacterial, viral and protozoan infections including primary, secondary and asymptomatic co-infections for a complete infection profile. The assay is based on a combination of multiplex, PCR and biochip array hybridisation. Innovative PCR priming technology permits high discrimination between multiple targets. A unique primer set is designed for each target which will hybridise to a complimentary oligo-nucleotide probe spotted on a biochip discrete test region (DTR).
The combination of priming and spatially organised biochip array technology enables enhanced specificity of the assay. Analysis can be completed from template DNA through PCR to data readout in less than 6 hours. The array is validated for urine and swab sample matrices with up to 53 patient samples being processed simultaneously. The array is CE marked for routine clinical use.
Our STI Multiplex Array II includes tests for the following STIs;
Neisseria Gonnorrhoea (NG) Mycoplasma Genitalium (MG)
Ureaplasma Urealyticum (UU) Chlamydia Trachhomatis (CT)
Tricomonas Vaginalis (TV) Haemophilus Ducreyi (HD)
Mycoplasma Hominis (MH) Treponema Pallidum (TP)
Herpes Simplex virus I (HSV-1) Herpes Simplex Virus 2 (HSV-2)
Randox Biosciences also offer four additional Molecular arrays.
For more information on our Molecular arrays please contact us by sending an email to Info@randoxbiosciences.com
What is Lyophilisation?
Lyophilisation or ‘freeze drying’ is the process by which water is removed from a product after it is frozen and placed under a vacuum, allowing the ice to change directly from solid to vapor without passing through a liquid phase. The process consists of three separate processes:
- Primary Drying (Sublimation)
- Secondary Drying (Desorption)
There are many benefits to using a lyophilised control including; improved product shelf-life and enhanced stability of volatile analytes. For example, many lyophilised controls have a shelf life of up to four years from the date of manufacture resulting in a reduction of costly new lot validation studies. Furthermore, lyophilised controls can be aliquoted and refrozen to extend the working stability of the product.
Reconstituting Lyophilised QC Material
The process of reconstitution involves adding a specified volume of distilled water to lyophilised QC material. The water should completely dissolve the lyophilised contents, giving a liquid solution, which is ready for analysis.
Reconstitution is a straightforward process, but requires a high level of precision. Small errors can have serious implications to the reconstituted material:
- If too much water is pipetted during reconstitution, the material will be heavily diluted and results will be lower than expected
- If too little water is pipetted during reconstitution, the material will not be sufficiently diluted, and results will be higher than expected
- If the correct volume of water is pipetted, but a small amount of water gets stuck in the pipette tip due to poor pipetting technique, results will be higher than expected
If a lyophilised control has been reconstituted incorrectly the contents of the vial will be wasted. It is therefore vitally important that controls are reconstituted with care.
Materials and Methods Required
The list of requirements for an accurate and consistent reconstitution technique is not extensive, but each requirement is vital. Labs should have:
- Calibrated volumetric pipettes
- Sterile, appropriately sized pipette tips
- Distilled water, or other reconstitution fluid as specified
- Technician with good pipetting technique
- Lyophilised QC stored according to manufacturer’s specifications
How to Reconstitute Lyophilised QC Material
Each different lyophilised control may require slightly different preparation, always refer to the instructions for use before reconstituting control material. The below guide provides a general overview of the reconstitution process, using the Randox Human Assayed Chemistry Premium Plus control (HN1530) as an example
- Place the vial of lyophilised QC on a flat surface, carefully remove the lid and the rubber stopper making sure not to spill any material
- Using a calibrated pipette and sterilised pipette tip, add exactly 5ml of distilled water directly into the QC vial, ensuring no water is left in the pipette tip, or on the rim/side of the vial
- Place the rubber stopper and lid firmly back onto the QC vial, and leave to stand for 30 minutes
- After 30 minutes, gently invert the QC vial 10-15 times to ensure the contents is completely dissolved, making sure to avoid the formation of foam. It is important that you DO NOT SHAKE the vial. Alternatively place the vial on a roller for 30 minutes to ensure the contents is thoroughly mixed
- Once satisfied all material has been completely dissolved, proceed to use the QC product in accordance with the ‘Control’ section of the individual analyser application
- Once finished, refrigerate any unused material. It is good practice to label the vial with the date of reconstitution to prevent the use of material outside of the recommended stability period
- Prior to reusing lyophilised material, mix the contents thoroughly by gentle inversion, as highlighted in Step 4
It is important to remember that there may be slightly different reconstitution requirements for different QC material. For this reason, it is vital that the instructions provided on the QC Kit Inserts are closely followed.
Reconstituting lyophilised QC can be time-consuming. Therefore, Randox Acusera offer convenient 5ml distilled water serum diluent to assist laboratories with reconstitution of lyophilised controls. These user-friendly pour over vials streamline the reconstitution process and eliminate the risk of pipetting errors.
If you have any further questions regarding lyophilised controls or would like to contact us, please do so by emailing us at email@example.com or use the contact us button provided.
Within any business, companies seek to outline clear methods in which employees should act and behave whilst carrying out their roles. These rules are outlined in company workplace policies. Every business – no matter which industry it operates in – should have well-documented and comprehensive workplace policies and procedures in place.
According to the Employment Law Handbook, a workplace policy is a set of rules and principles that aims to provide guidance to managers and workers in how to behave in the workplace. They can be in place for numerous different issues – bullying, harassment, internet use, health and safety are just a few that can be implemented.
Health and Safety
As mentioned above, health and safety is an important aspect of any workplace policy. The health and well-being of the working community is of utmost importance for sustainable development. Specifically, a drug and alcohol policy is a key part of the overall health and safety policy within a company. Alcohol and drugs through their effects on health, safety, work performance and absenteeism can jeopardise productivity, deny businesses the leading edge and curtail competitiveness. Effectively implemented drug and alcohol policies will help employers in the legal duty to protect the health, safety and welfare of employees.
The need for a Drug and Alcohol Policy
Drugs and alcohol misuse can have dangerous consequences within the workplace. All organisations can benefit from an agreed policy that applies to all staff. There are wide range of statistics available to highlight the worrying impact that drugs and alcohol can have on individuals. In 2016, it was estimated that £7 billion was lost in productivity through unemployment and sickness. Furthermore, 10.8 million adults in England are drinking at levels that pose some risk to their health. A survey carried out by UK based Health and Safety Consultants Protecting.co.uk showed that; from 2,600 workers in office, factory, retail and the public sector, 85% admit to being drunk at work in the last year; not including the Christmas party. 28% of those surveyed admitted using drugs at work, including NPS (formerly legal highs) cannabis and other illegal substances.
From a legal point of view, employers have a duty of care under the Health and Safety at Work Act 1974 to ensure, as far as is reasonably practicable, the health, safety and welfare at work of employees. Also, under the Management of Health and Safety at Work Regulations 1999, to assess the risks to the health and safety of employees. If an employer knowingly allows an employee under the influence of drug misuse to continue working and his/her behaviour places the employee or others at risk, they may face prosecution.
Advantages of having Policies in place
Having well-developed policies and procedures can provide a range of benefits to an organisation. An effectively implemented drug and alcohol policy will ensure a clear understanding within the workplace of the rules relating to drugs and alcohol. It will also provide a greater awareness in workplaces of the effects of drugs and alcohol an consequently early recognition. Furthermore, it ensures that the necessary structures and procedures are in place should a problem arise. An up to date policy will also provide assurance that key staff have been trained to understand the issues involved and have the necessary skills to deal with any problems should they arise.
How can Randox Testing Services help?
At Randox Testing Services we offer a comprehensive consultancy service to help employers create, an effective substance misuse policy. By providing this service we offer practical advice, guidance and support in composing a substance misuse policy.
Our confidential policy review service provides assistance to employers with an existing substance misuse policy. With this service, we help to modify existing documents to ensure it is legally viable and can withstand challenge in court.
To read more on workplace policies and their importance within an organisation, click here.
Are you taking part in Dry January? Giving up alcohol can do your insides a lot of good, and it’s great news for your liver in particular. It may be that after the festive period our liver needs a little bit of rest!
Did you know that alcohol consumption across the UK increases by a staggering 41 percent more than the annual monthly average in December? That’s more than anywhere else in the world.
The effects of alcohol on your health really depend on how much you drink and how often, but as the statistics show, more of us increase our uptake of alcohol over the festive period.
So how does this impact our body?
The results of over indulging vary from a hangover, a poor night’s sleep, to causing an irregular heartbeat, and in some cases, excessive alcohol intake can lead to liver damage. This can be a very serious condition, given the liver’s vital role in the body.
The liver plays a central role in all metabolic processes. In fat metabolism, it breaks down fats and produces energy. When we intake alcohol or drugs, the liver metabolizes the drug and detoxifies chemicals. And it also makes proteins important for blood clotting and other functions.
Following these processes, the liver also secretes bile that ends up back in the intestines and helps the digestion of fats and oils, otherwise known as lipids.
As Randox Health Expert Dr. Gary Smyth explains:
“The liver is one of the most complex organs in the body and also one of the most important. Although it is very resilient, each time it has to filter alcohol some of its cells die. The liver can develop new cells, but abuse over a prolonged period reduces its ability to regenerate, causing serious damage.”
It is not just heavy drinking over years that can cause liver disease – binge drinking is also a culprit and can lead to your liver becoming fatty and inflamed. The best advice is to drink in moderation. Simple tips like taking a glass of water in-between alcoholic drinks are key to staying hydrated.
Know your units;
- According to drinkaware.co.uk, unit guidelines are now the same for men and women.
- Both are advised not to regularly drink more than 14 units a week
- This equates to 6 pints of 4% beer / 6 glasses of 13% wine / 14 glasses (25ml) of 40% spirits
- But don’t save up your 14 units, it’s best to spread evenly across the week.
- If you want to cut down the amount you’re drinking, a good way is to have several drink-free days each week.
- If you’ve had a heavy drinking session, avoid alcohol for 48 hours.
What does one unit of alcohol look like?
One unit of alcohol is the amount of alcohol an average adult can process within one hour so that so that there’s no alcohol left in their bloodstream.
One unit of alcohol equates to:
- 218ml of standard 4.5% cider
- 76ml of standard 13% wine
- 25ml of standard 40% whiskey
- 250ml of standard 4% beer
- 250ml of a standard 4% alcopop
How many units are in my drink?
- Small glass white / rosé / red wine (125ml 12%) = 1.5 units
- Standard glass white / rosé / red wine (175 ml 12%) = 2.1 units
- Large glass white / red / rosé wine (250ml 12%) = 3 units
- Pint of lager / beer / cider (5.2%) = 3 units
- Bottle of lager / beer / cider (330ml 5%) = 1.7 units
- Single small shot of spirits (25ml 40%) = 1 unit*
*taken from NHS Live Well Guidelines
Having your liver health checked after Christmas is a great way of tracking any changes that you may need to make to your lifestyle, for better or for worse – essential for helping you prevent liver disease and allowing you to take early action if it is diagnosed.
At Randox we offer a comprehensive menu of liver function tests to determine the health of your liver. Provided by Randox to a wealth of hospitals, laboratories and research facilities across the globe, these tests are also directly available to you, the consumer, via our Randox Health clinics.
- Alanine Aminotransferase (ALT) – an enzyme mainly found in the liver. Liver injury or disease will release ALT into the bloodstream, thus elevating serum ALT levels. Moderately high or mildly elevated ALT levels can be associated with chronic liver disease, such as cirrhosis, which is scarring of the liver.
- Aspartate Aminotransferase (AST) – an enzyme found predominantly in the heart, liver and skeletal muscles. Cell injury or disease will release AST into the bloodstream, thus elevating blood AST levels. Increased AST levels may be associated with hepatitis (inflammation of the liver), cirrhosis (scarring of the liver), or drug-induced liver injury.
- Gamma-Glutamyltransferase (GGT) – an enzyme found mainly in the liver. Increased levels of GGT in the blood may indicate bile duct injury, hepatitis (inflammation of the liver), cirrhosis (scarring of the liver), liver necrosis (death of liver tissue), liver tumours or the use of drugs that are toxic to the liver. A high GGT level is frequently associated with increased alcohol consumption, as this liver enzyme is involved in the breakdown and removal of alcohol from the body.
- Glutamate Dehydrogenase (GLDH) – an enzyme located within the mitochondria (energy-producing machinery) of cells, particularly within liver tissue. Significant liver cell damage may cause release of GLDH into the bloodstream. Toxic liver damage, liver cell necrosis (cell death) or hypoxic liver disease (where liver cells are deprived of oxygen) may cause an increase in GLDH. Measurement of GLDH in combination with other liver markers may help distinguish between different causes of liver dysfunction.
- Bilirubin – a yellowish-brown pigment found in bile (a fluid produced in the liver that facilitates digestion in the intestine). Increased levels may be associated with liver or bile duct blockage (eg due to gallstones), hepatitis (inflammation of the liver), cirrhosis (scarring of the liver), trauma to the liver, a drug reaction, long-term alcohol abuse or rare inherited disorders (eg Dubin-Johnson syndrome which is characterised by mild jaundice).
- Albumin – produced by the liver, albumin is the most abundant protein in the blood. Albumin plays in important role in maintaining blood pressure and transporting a wide variety of small molecules, such as hormones, vitamins and drugs, throughout the body. Various conditions are associated with decreased albumin levels, including kidney and liver diseases.
- Copper – an essential mineral that plays a part in many enzyme systems within the body. Excess or deficiency of copper is very rare, however raised copper levels may be caused by chronic liver disease or acute hepatitis (inflammation of the liver).
And when used in conjunction with the wide variety of other tests available within the world’s most comprehensive and personalised health testing menu, you can obtain an understanding of your full body health like never before.
That’s why we don’t test in isolation, which can give a patchy representation of your health and can fail to pick up on related symptoms elsewhere in the body. We test up to 350 tests across 25 areas of your health – giving you the power to take your health into your own hands.
Contact the Randox Health team today to determine the health of your liver, and of your body.
Call 0800 2545 130 or click here.
With Randox Health, you can make a real difference to your life, not just for this New Year but for many New Years.
Whether you are planning a family and want a profile of your fertility, want to know the likelihood of developing an illness that runs in the family, or simply want to get fit, the world’s most comprehensive and personalised health check is now available to you. You can start the New Year with an understanding of your body like never before.
Instead of looking at isolated sections of your health, Randox Health takes a whole-body approach to your health, to not only be able to diagnose any existing conditions at an early stage, but also forecast any health problems in your future, enabling you to take a long-term view of your health.
This holistic style of testing ensures that the patient understands their full body health in the greatest detail possible. Randox Health can analyse over 350 markers of health and disease within your body simultaneously, across 25 different aspects of your health, including heart health, diabetes health, thyroid, lung, digestive and nutritional health. The ability to carry out hundreds of tests combined in one check provides much more information and ultimately a more accurate diagnosis.
By determining your physiological and chemical wellbeing, the diseases at which you are personally at risk of developing in the future, and areas for improvement, you can embark on your Get Healthy Journey equipped with the knowledge and know-how used by the world’s best scientists.
And with results, a consultation with a Randox Health expert, and follow-up testing all included within your 12-month health programme, you can enter 2018 knowing that Randox Health will look after you every step of the way. Your health programme gives you the power to take control of your health, not leaving it to chance in 2018 or in the future.
All that’s left for you to do, is to enjoy the year with your family and friends.
Book your Randox Health Programme by clicking here, or contact our team by phone 0800 2545 130 or by email firstname.lastname@example.org
Pet Food companies worldwide are working towards constantly improving and maximising the quality of their product. The problematic topic of mycotoxin contamination in pet feed is quickly becoming a major cause for concern. This is due to the risk they pose for animal health and with the increasing prevalence of mycotoxins globally the focus is on pet food companies to meet EU and FDA regulations and maximise the quality of their product.
What are Mycotoxins?
Mycotoxins are naturally occurring metabolites that are produced by certain moulds and with the ability to develop and grow on a variety of crops they can affect large amounts of feed and increasingly, pet food. If a sample tests positive even for low levels of contamination the toxins are still strong enough to cause illness in animals, and if low levels are consumed over a long period of time this can result in chronic illnesses including; cancer, organ damage and neurological disorders.
The main mycotoxins of concern in pet food are;
- Deoxynivalenol (DON)
- Fumonisins (FUM)
- Zearalenone (ZEN)
- T-2 Toxin
Contamination can occur in any country around the world and at any stage of production. Herein lies the issue of how to prevent mycotoxin pollution, to tackle the issue head on and work towards a mycotoxin free product is the joint responsibility of feed producers, supply chain partners and quality control laboratories ensuring the complete safety of the product.
How can you tell if an animal has ingested pet food contaminated with mycotoxins?
In terms of animal health, mycotoxins can cause a variety of problems. Severity and symptoms can vary from animal to animal but general symptoms include; hyperactivity, vomiting, high temperature and loss of coordination. If you suspect your pet has been affected by mycotoxins you must bring them to the vet for immediate treatment.
The European Union currently regulate all the mycotoxins listed above and are subject to maximum or recommended residue limits. In the US, FDA regulations are limited to aflatoxins, DON and fumonisins, see table below for FDA regulations. If mycotoxin levels in feed fail to meet FDA standards, mass amounts of feed may need to be destroyed as grain producers are prohibited from mixing contaminated feed with clean feed to reduce the mycotoxin levels.
|Immature Animals||Aflatoxins||Corn/ peanut/ other ingredients||20 ppb|
|Adult Pets||Aflatoxins||Corn/ peanut/ cottonseed meal/ other ingredients||20 ppb|
|DON||Grain/ grain byproducts, not to exceed 40% of diet||5 ppm|
|Fumonisins||Corn/ corn byproducts, not to exceed 50% of the diet||10 ppm|
How do we tackle the problem?
Safe, reliable screening solutions for different variations of mycotoxins are available that can ensure only mycotoxin free feed is produced. Randox Food Diagnostics have created mycotoxin screening platforms as a response to increased levels of mycotoxins being found in feed globally.
The platforms use patented Biochip Array Technology (BAT) so pet food producers can test for multiple toxins from a single sample. Randox Food Diagnostics have a range of mycotoxin Biochip Arrays available with customised arrays available to suit the specific screening needs of certain producers. Each Biochip format uses a straightforward extraction process with a 50µl sample of feed, available tests include; Fumonisins, Ochratoxin A, Aflatoxin G1/G2, Aflatoxin B1, Paxiline, Ergot Alkaloids, Diacetoxyscirpenol, Deoxynivalenol, T2 Toxin and Zearalenone.
For more information on mycotoxin screening with Randox Food Diagnostics contact email@example.com
Earlier this year the World Obesity Federation made the stark statement that: “The early diagnosis and treatment of childhood obesity could be considered similar to vaccination.”
Essentially, they want to see this condition treated in the same way as chicken pox, measles and mumps: tackled – in the hope of eradication – by a strategic approach founded on proactive policies and early prevention.
Obesity in children and adolescents has risen tenfold in the last 40 years, according to a recent study by The Lancet. In Britain, one in ten young people aged between 5 and 19 is obese. Worryingly, the prevalence of obesity is actually higher in younger children than older ones.
The WHO first called for obesity to be understood as a disease in 1948, but back then it wasn’t even considered a risk factor for cardiovascular disease. In 1997 the WHO held a special conference on obesity and stated that: “the global epidemic projections for the next decade are so serious that public health action is urgently required.”
Then it was alarmed that the prevalence of men with a BMI greater than 30 was 15% and 16.5% in women. To think that it has now risen dramatically to 67% for men and 57% for women, highlights just how serious a problem obesity poses to society.
The calls for more countries to officially recognise it as a disease is based on the position that obesity meets the definition of a chronic, relapsing, progressive disease that causes organ damage.
Women and men who are obese are 12.5 and 5.2 times (respectively) more likely to develop diabetes than people who are a healthy weight. 90% of people with Type 2 diabetes are obese.
People with diabetes are then at a greater risk of a range of chronic health conditions including cardiovascular disease, blindness, amputation, kidney disease and depression than people without diabetes. Diabetes leads to a two-fold excess risk for cardiovascular disease, and diabetic retinopathy is the leading cause of preventable sight loss among people of working age in England and Wales. About one in twenty people have diabetes, yet people with diabetes account for one quarter to one third of hospital admissions for cardiovascular disease.
According to Government figures released this year, people who have Type 2 diabetes are 28.4% more likely to die early than their peers.
Getting in front of this wave of diabetes will not only bring down the numbers of people affected but also see a positive impact on the numbers of obese people. As with all conditions – the earlier they are identified, the better. To do this, new methods of diagnosis are being developed.
A radical new test for a protein found in our blood called adiponectin can identify pre-diabetes. This is a game-changing diagnostic tool that empowers people with the knowledge that they are at risk, but may be able to avoid it through relatively simple lifestyle changes.
The adiponectin test is available from Randox – both for clinical use and also through our Randox Health clinics. We have developed the most comprehensive health checks available on the market. These are so sensitive that in a range of conditions including diabetes we are able to identify signs of pre-illness. This enables clients to make often simple changes to stay healthy.
We know that prevention works. The NHS carried out a study in 2016 which revealed an average 26% reduction in new cases of Type 2 diabetes in those participating in a diabetes prevention programme, compared with usual care.
To find out more, click here.
For further information please email: firstname.lastname@example.org
Chronic Kidney Disease (CKD) is a long term condition which involves the progressive loss of kidney function a late diagnosis can result in end stage renal disease requiring kidney dialysis or transplantation. Typically, CKD is result of a combination of other conditions which puts a strain on the kidneys, these conditions can include high blood pressure, diabetes and high cholesterol amongst many other ailments.1
Randox Biosciences are continually researching and developing new tests, targeting various health concerns around the world to improve diagnostics and health worldwide. Recently, our dedicated scientists have developed a new test, utilising our proprietary Biochip Array Technology (BAT) that simultaneously and quantitatively detects multiple early biomarkers associated with kidney damage allowing for earlier intervention and treatment, preventing further kidney damage.
We offer two multiplex Chronic Kidney Arrays as shown below:
Early detection provides those diagnosed with the opportunity to alter their lifestyle in order to improve their kidney and overall health, whether that is through the reduction of salt in their diet, increased physical activity and alcohol limitation.
To find out more about the Chronic Kidney Disease Arrays offered by Biosciences email email@example.com
1 NHS – https://www.nhs.uk/conditions/kidney-disease/
In 2002, Randox invented a worlds first; Biochip Array Technology, instantly changing the landscape of diagnostic testing forever. Biochip Array Technology is a multi-analyte platform which provides an unrivalled increase in patient information per sample. Instead of a patient sample needing to be subdivided for each test result, or in some cases re-collected, Biochip Array Technology offers a diagnostic patient profile with each patient sample.
How does it work?
Biochip Array Technology is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
The biochip detection system is based on a chemiluminescent reaction. This is the emission of light, without heat, as a result of a chemical reaction. An enzyme is used to catalyse the chemical reaction on the biochip which generates the chemiluminescent signal. The light emitted from the chemiluminescent reaction that takes place in each DTR is simultaneously detected and quantified using a Charge-Coupled Device (CCD) Camera.
Each biochip has up to 49 Discrete Test Regions (DTR). This means that up to 44 tests can be carried out simultaneously. The additional DTR are reserved for internal quality control and visual reference, a unique Biochip Array Technology feature.
How is the technology applied?
With over £250 million invested into Biochip Array Technology research and development, Randox have launched a range of Biochip Array Technology immunoanalysers – The Evidence Series. This includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser is developed with boundary pushing engineering, designed to make financial, labour and time savings for the end user.
The Evidence Series has truly revolutionised diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.